Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors and Lymphomas
Recruiting1 awardPhase 2
Detroit, Michigan
This trial will test how well selpercatinib works in treating patients with advanced solid tumors, lymphomas, or histiocytic disorders that have activating RET gene alterations.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.